Researchers Discover New Clues For The Initiation And Regulation Of Immune Response

March 06, 1998

HERSHEY, PA-- Researchers at Penn State's College of Medicine have discovered that the development and function of natural T cells are controlled by a molecule called CD1d1.

Natural T cells are specialized cells that are part of white blood cells. These cells are key components of the immune system and help the body fight disease.

In the March 6 issue of Science, Sebastian Joyce, Ph.D., assistant professor of microbiology and immunology at Penn State's College of Medicine and his collaborators, Dr. Robert Cotter of the Johns Hopkins School of Medicine and Drs. Jonathan W. Yewdell and Jack R. Bennick of the National Institutes of Health, and their co-workers report a biochemical clue as to how CD1d1 might control natural T cells' function in their paper entitled, "Natural Ligand of Mouse CD1d1: Cellular Glycosylphosphatidylinositol."

"We found that CD1d1 associates with a small chemical component of cells called glycolipids. Glycolipids are fatty acids modified by sugars. Therefore, we predict that cellular glycolipids when associated with CD1d1 transduce signals that "turn-on" natural T cells, which helps the body fight disease," says Joyce.

He adds, "The finding of a cellular glycolipid in association with CD1d1 is just the beginning of the solution of a major puzzle as to how natural T cells control immune function."

Recently, investigators at Harvard Medical School have reported that natural T cells either develop poorly or are dysfunctional in individuals predisposed to or afflicted with autoimmune insulin-dependent diabetes mellitus. Additionally, investigators at Chiba University in Japan have reported that natural T cells are required for immunity against cancer cells. Thus, how the immunoregulatory natural T cell accomplishes its function is not only of fundamental importance but has clinical relevance.

This work was supported by the National Institutes of Health, The Juvenile Diabetes Foundation, International and American Cancer Society.

Joyce and his colleagues are now working to further understand what glycolipid of the host and pathogens specifically "turn-on" natural T cells. Understanding this process should lead to the design of therapeutics for diseases such as autoimmune diabetes, cancer and persistent bacterial and parasitic infections.

Leilyn Perri
(717) 531-8604
lperri@psghs.edu

M. Steven Bortner
(717) 531-8606
-end-


Penn State

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.